Project Grant R42CA224646

This $255,730 National Science Foundation project grant supports the development of self-assembling molecular brachytherapy for treatment of metastatic cancer. The goal is to enable radiation therapies for metastatic cancer, which accounts for approximately 90% of cancer deaths in the United States each year. The grantee, Oncurie, LLC, seeks to advance a radiotherapy approach that exploits cancer cells themselves as catalysts for therapeutic delivery. Specifically, the company will develop an...

This $384,863 Project Grant award from the National Institute of Biomedical Imaging and Bioengineering (NIBIB) under the "Discovery and Applied Research for Technological Innovations to Improve Human Health" (CFDA 93.286) program supports research to develop a novel radiotracer imaging agent for detecting Gram-positive bacterial infections associated with implanted medical devices. The key products and services to be delivered include: In vitro testing of a bivalent radiotracer agent...

This $275,000 Small Business Technology Transfer (STTR) Phase I grant from the National Science Foundation (CFDA 47.084 - NSF Technology, Innovation, and Partnerships program) was awarded to Oncoblaze LLC to develop a novel device for targeted delivery of chemotherapy agents to tissue surrounding surgically removed tumors. The project aims to address the issue of tumor recurrence after cancer surgery, which affects 30-40% of patients for certain cancers. The device uses an infrared laser to heat...

Federal Project Grant Award Summary Intra Therapeutics, LLC received a $398,039 Project Grant award from the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395), effective September 18, 2025, with completion targeted for August 31, 2026. The company is developing localized immunotherapy treatment for triple-negative breast cancer utilizing an injectable hydrogel platform called XCSGel formulated with Interleukin-12 (IL-12). The research focuses on optimizing...

Federal Project Grant Award Summary Persistence Therapeutics, Inc. received a $629,370 Project Grant award from the National Cancer Institute under the Cancer Treatment Research program (CFDA 93.395) on September 22, 2025, with a completion date of August 31, 2026. The award supports development of SYNTHNODE, an implantable biomaterial scaffold device approximately the size of a dime that functions as a synthetic lymph node to manufacture potent Chimeric Antigen Receptor (CAR) T cells. This...

Teliatry Inc. received a $768,138 project grant award from the National Institutes of Health's National Institute of Biomedical Imaging and Bioengineering to develop a minimally invasive, single incision, rechargeable spinal cord stimulation system for chronic pain management. The grant was awarded under the Discovery and Applied Research for Technological Innovations to Improve Human Health program. Through this award, Teliatry will engineer the world's smallest (0.75cc), most cost-effective...

This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides funding of $799,962 to Tripill Biotechnology, Corp. to develop radiolabeled PSMA agents with low salivary gland uptake for improved prostate cancer imaging and therapy. The key products and services to be delivered include: Constructing PSMA derivative compounds, such as NOTA-UNC-PSMA2, that can selectively reduce salivary gland uptake while maintaining high tumor uptake in prostate...

Federal Grant Award Summary Fusion Energy Solutions, Inc. (doing business as Serva Energy) received a $1.99 million Project Grant from the National Cancer Institute under the Cancer Treatment Research program (CFDA 93.395) on September 18, 2025, to develop Good Manufacturing Practice (GMP)-grade Terbium-161 as a therapeutic radiopharmaceutical for cancer treatment. This direct-to-Phase II Small Business Innovation Research (SBIR) award, scheduled for completion by August 31, 2027, addresses...

Federal Grant Award Summary EF Therapeutics Corp. received a $984,830 Project Grant award from the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395) on September 4, 2025, with a completion date of August 31, 2027. The award funds the development and validation of the IntelliPulse™ platform technology, a next-generation delivery system designed to enhance pulse electric field (PEF)-based therapeutic applications for cancer treatment. Specifically, the...

This federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $457,683 to the Beckman Research Institute of the City of Hope to develop and evaluate novel "Bio-Beacons" - tumor-targeting bacterial vectors engineered to secrete chemokines and cytokines. The goal is to increase the density of tumor-reactive immune cells, such as CD8 T cells, CD4 T cells, dendritic cells, and natural killer cells, within solid tumors. This is...